KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Impact · against what's priced in

Keros Therapeutics' Q2 earnings miss and lack of revenue reinforce its status as a high-risk, pre-revenue biotech. While the loss per share was wider than expected, the primary valuation drivers remain the long-term cash runway and the clinical progress of its DMD study.

KROS−0.20

No priced-in read yet

In context

The company missed earnings estimates with a loss of $1.45 per share against a $1.25 estimate and reported zero revenues, though it maintains a cash runway into H1 2028 and progress in its DMD phase II study.

Read from the article alone

• earnings
• healthcare
• biotech
• KROS
• loss
• r and d
• restructuring

Search tags